Literature DB >> 28344940

VISUAL OUTCOME WITH A MULTIMODALITY APPROACH IN A CASE OF RHINOORBITO- CEREBRAL MUCORMYCOSIS.

A C Kothari1, S Shroff1.   

Abstract

BACKGROUND: Rhinoorbito-cerebral mucormycosis is an uncommon and acute fungal infection which runs a fulminant course. Uncontrolled diabetes mellitus is the most common predisposing factor. AIM: To assess the outcome of a poorly controlled diabetic with Rhinoorbito-cerebral mucormycosis using a multi-modality management.
METHODOLOGY: We report a case of a 57-year old male who presented to us with proptosis and total external ophthalmoplegia diagnosed with rhino-orbito-cerebral mucormycosis. Patient was started on conventional intravenous amphotericin B to which he developed systemic toxicity. As an alternative, a combination therapy of oral posacanazole along with peribulbar amphotericin B injections for a more localised effect was initiated.
RESULTS: He had a favourable outcome with dramatic improvement in vision and marginal recovery of extra ocular movements within 20 days of initiation of combination therapy.
CONCLUSION: Rhinoorbito-cerebral mucormycosis is a major diagnostic dilemma with quick progression and a high mortality. Prompt medical management with a multi-modality approach can save the patient from orbital exenteration.

Entities:  

Keywords:  Amphotericin B; Good outcome; India; Mucormycosis; Posaconazole; Uncontrolled diabetes

Year:  2016        PMID: 28344940      PMCID: PMC5342625     

Source DB:  PubMed          Journal:  J West Afr Coll Surg        ISSN: 2276-6944


  13 in total

1.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

Review 2.  Disseminated rhinocerebral mucormycosis: a case report and review of the literature.

Authors:  Brian M O'Neill; Anthony S Alessi; Elsa B George; John Piro
Journal:  J Oral Maxillofac Surg       Date:  2006-02       Impact factor: 1.895

3.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

4.  Intraorbital Irrigation of Amphotericin B in the Treatment of Rhino-Orbital Mucormycosis.

Authors:  Zachary P Joos; Bhupendra C K Patel
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 Jan/Feb       Impact factor: 1.746

5.  Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes.

Authors:  A Bhansali; S Bhadada; A Sharma; V Suresh; A Gupta; P Singh; A Chakarbarti; R J Dash
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 6.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes.

Authors:  Suneetha Nithyanandam; Moire S Jacob; Ravindra R Battu; Reji K Thomas; Majorie A Correa; Ophelia D'Souza
Journal:  Indian J Ophthalmol       Date:  2003-09       Impact factor: 1.848

Review 8.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

9.  Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases.

Authors:  N A Parfrey
Journal:  Medicine (Baltimore)       Date:  1986-03       Impact factor: 1.889

10.  Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Authors:  Dounia Bitar; Dieter Van Cauteren; Fanny Lanternier; Eric Dannaoui; Didier Che; Francoise Dromer; Jean Claude Desenclos; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.